Buy CJC-1295 + Ipamorelin in Canada
Hormonal, Growth Hormone & Body Composition Research
Buying CJC-1295 comes down to two letters: DAC. There are two different compounds sold under nearly the same name, and they behave nothing alike. The Vistara Labs blend uses CJC-1295 without DAC, and once that distinction is clear the rest of the decision is straightforward.
View product →At a glance: Vistara Labs stocks CJC-1295 + Ipamorelin (no DAC) in 10 mg vials and as a ready-mixed nasal spray, independently tested, with a certificate of analysis on our Lab Reports page, shipped from within Canada by Canada Post Xpresspost, with same-business-day dispatch on orders before 3 pm Pacific. We deliver to every province, including Ontario, Quebec, British Columbia and Alberta.
CJC-1295 with DAC vs without DAC
CJC-1295 is a growth hormone releasing hormone (GHRH) analogue. The DAC (Drug Affinity Complex) is an added molecule that binds the peptide to albumin in the bloodstream, and it changes the compound’s behaviour completely.
- With DAC: albumin binding stretches its presence out to something measured in days.
- Without DAC (often listed as Mod GRF 1-29): no albumin binding, and it clears in roughly half an hour.
Those are two genuinely different research materials, and the distinction shapes any study built around them, from sampling schedules to how long the compound stays in circulation.
Why it is usually paired with ipamorelin
CJC-1295 and ipamorelin act on different receptors. CJC-1295 is a GHRH analogue; ipamorelin is a ghrelin receptor agonist, and a notably selective one. Research pairs them precisely because they are two separate pathways rather than two versions of the same lever, which is why the blend is far more commonly studied than either alone.
Buying CJC-1295 + Ipamorelin in Canada
Neither compound is approved for human use in Canada. No pharmacy stocks them, no prescription exists, and everything sold is supplied strictly as a research material for laboratory use.
Lab reports. Certificates of analysis from independent laboratories are published for each compound on our lab reports page, with purity above 99 percent. The blend arrives as a lyophilised powder, which keeps well stored cold and dry until it is reconstituted.
Research context. CJC-1295 without DAC is a 29-amino-acid GHRH fragment carrying four amino acid substitutions that make it far more stable than natural GHRH, which the enzyme DPP-4 breaks down within minutes. Paired with ipamorelin, it is studied in work on pulsatile growth hormone release.
The Vistara Labs CJC-1295 + Ipamorelin blend
- No DAC. The blend uses CJC-1295 without DAC, also known as Mod GRF 1-29, the short-acting form described above.
- 5 mg + 5 mg in a 10 mg vial. Each vial holds 5 mg CJC-1295 and 5 mg ipamorelin, both listed on the product page, and a pack of ten vials is also available.
- Tracked delivery to every province. Shipped orders travel with tracking, so you can follow the parcel to the door.
- Supplied for laboratory research. The blend is supplied for research use only and is described here by its chemistry.
Vistara Labs stocks CJC-1295 + Ipamorelin 10 mg (no DAC) as a lyophilised blend, shipped from within Canada to every province.
Frequently asked questions
Is CJC-1295 the same as Mod GRF 1-29?
Mod GRF 1-29 is the common name for CJC-1295 without DAC. The DAC version is a different compound with a much longer duration.
Can you buy CJC-1295 and ipamorelin in Canada?
As research materials, yes, from Canadian research suppliers. Neither is available as a medicine in Canada.
Why are they sold together?
Because they act on different receptors, GHRH and ghrelin, so the blend is what most of the research literature actually examines.
Will an order be stopped at customs?
Every order ships from within Canada, so there is no customs step. It travels as an ordinary domestic parcel.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
References
The published human CJC-1295 trial used the long-acting DAC analogue, not the no-DAC form. Ipamorelin has its own human pharmacokinetic study. No trial of the two combined was identified.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsRandomised placebo-controlled trial in healthy adults — of the LONG-ACTING (DAC) CJC-1295 analogue, not the no-DAC form.
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersHuman pharmacokinetic/pharmacodynamic study; five escalating infusion levels, eight healthy male subjects per level.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
